FLT3 and acute myeloid leukemia: The patient is a 73-year-old woman with a history of R/R AML with multiple mutations including in FLT3. She failed traditional chemotherapy and was initiated on combination therapy with the lysine-specific demethylase-1 inhibitor iadademstat and gilteritinib as part of the FRIDA trial (NCT05546580).